Coagulation A bnormalities in Subarachnoid Hemorrhage
Introduction
• This report describes changes in coagulation and fibrinolytic mechanisms which may accompany subarachnoid hemorrhage. The specific study objectives were to seek answers to the following questions: (1) Are systemic clotting abnormalities detectable following subarachnoid hemorrhage? (2) If so, do they have any prognostic implications regarding gross mortality or rebleeding episodes from aneurysms? (3) If any of the above correlations are positive, can the clotting abnormalities themselves be responsible for an undesirable result, or do they simply accompany such results? (4) If the clotting abnormalities contribute in some way to an undesirable result, can they be altered to effect a better result? This report attempts to answer the first and possibly the second questions posed above in the affirmative.
Method
A coagulation test batteryt was utilized in the 
Results
The following tests in subarachnoid hemorrhage patients did not differ significantly from the controls: prothrombin time, platelets, antithrombin, thromboplastin generation time, thrombin time, thromboelastogram values R and MA, assay of factors II, V and VIII ( fig.  1) .
Test values revealing significant differ-
FIGURE 2
Tests revealing significant differences between patients and controls. possible significance of these abnormalities in relation to the problem of rebleeding from ruptured aneurysm. We were fortunate in having an opportunity to obtain the coagulation test battery 24 hours or less preceding a rebleeding episode in three patients who were initially hospitalized with a diagnosis of subarachnoid hemorrhage secondary to ruptured aneurysm (table 3) . In two of the three patients we were able to secure euglobulin lysis studies less than 24 hours ' preceding, and within 24 hours following, the rebleeding episode. In the third patient we obtained values before the rebleed, but not subsequently. It should be noted that although our study generally suggests an increased incidence of fibrinolytic activity following subarachnoid hemorrhage, in none of these three patients was there an increase in fibrinolytic activity preceding the rebleeding episode, and in two out of three there was no increased activity following the rebleed. We have, therefore, no direct evidence that fibrinolytic activity contributes to rebleeding from ruptured aneurysm.
Discussion
A number of reports have appeared in the recent literature concerning the effect of cerebrospinal fluid on systemic coagulation mechanisms. De Vivo, Kline and Dodge 2 were concerned with the possible adverse effect of shunting cerebrospinal fluid into the vascular system in hydrocephalic patients. They demonstrated significant acceleration of clot formation using thrombin and thromboplastin test systems. This effect was noted in from 76% to 83% of cerebrospinal fluid samples tested. They also demonstrated evidence for the presence of an inhibitory factor in normal cerebrospinal fluid when utilizing various prothrombin test systems. Niewiarowski et al. 3 concluded that factor V activity is present in cerebrospinal fluid. They also noted a trace of prothrombin activity and negligible factor VII and VIII activity in their cerebrospinal fluid samples. Wilkins et al. 4 explored the possibility that cerebrospinal fluid may influence the recurrent hemorrhage rate in intracranial aneurysm. In 50 normal cerebrospinal fluid samples no thrombin, fibrinogen, prothrombin, proconvertin, proaccelerin, factor VIII, or thromboplastic activity was found. They concluded that cerebrospinal fluid did not interfere with or in any way influence the healing of ruptured aneurysm.
Very few investigations into cerebrospinal fluid fibrinolytic activity have been reported. Roberts and Astrup, 5 in 1957, and Moltke 0 in 1958 demonstrated fibrinolytic activity in dura and pi a of various animal species. In 1958 Albrechtsen, Storm, and Classen 7 found an incomplete activator of fibrinolytic activity in human cerebrospinal fluid. Porter et al. 8 in 1969 confirmed the above results in humans and further investigated the ability of systemically administered fibrinolysin and E-aminocaproic acid (Amicar) to penetrate into the cerebrospinal fluid. Thrombolysin did not appear to penetrate the blood-brain barrier in animals, whereas aminocaproic acid did seem to alter the cerebrospinal fluid fibrinolytic activity in seven of the ten animals studied.
In view of the current interest in using E-aminocaproic acid to prevent rebleeding in patients with subarachnoid hemorrhage, this study was undertaken to assess coagulation and fibrinolytic abnormalities in patients with ETTINGER subarachnoid hemorrhage. Our data will be analyzed in the context of the questions posed in the introduction of this presentation as specific study objectives. (1) Are systemic clotting abnormalities detectable following subarachnoid hemorrhage? We have been able to identify abnormalities in at least five tests included in our coagulation test battery which appear to be frequently and significantly altered following subarachnoid hemorrhage. These tests are recalcification time, fibrinogen, partial thromboplastin time, the K value of thromboelastogram, and euglobulin lysis test.
(2) If so, do they have any prognostic implications regarding gross mortality and rebleeding from aneurysms? The only correlation made between gross mortality and the test values was noted in the fibrinogen determination. It was suggested that patients with fibrinogen values exceeding 400 mg% shortly after their bleeding episode had a very poor prognosis for survival. On the other hand, a low or normal fibrinogen was no guarantee of survival, as eight of the 22 patients with fibrinogen below 400 mg% also died. This gives us a mortality rate of 36% under 400 mg%, as compared with 87% above 400 mg%.
Regarding the second part of the question, "Is there any correlation between rebleeding from aneurysms and the tests performed," we were able to draw no positive correlations. However, in view of the current interest in the use of agents which inhibit fibrinolytic mechanisms as therapy to prevent rebleeding, it should be noted that in three patients studied just before rebleeding, there was no evidence of increased fibrinolytic activity.
These observations have direct implications regarding the use of aminocaproic acid or other fibrinolytic inhibitors for the treatment of subarachnoid hemorrhage in hopes of preventing rebleeding in such patients. The major hazard of such agents is that the lysis may be secondary to increased coagulation activity, and by administering effective doses the clotting abnormality proceeds unimpaired to result in widespread intravascular coagulation (consumption coagulopathy).
(3) If any of the above correlations are positive, can the clotting abnormalities themselves be responsible for an undesirable result, or do they simply come from such results? We have no evidence to suggest that these abnormalities precede or in any way r cause subarachnoid hemorrhage. We feel that these changes most likely reflect tissue damage and /or meningeal reactions occurring following the acute episode.
(4) If these clotting abnormalities do contribute in some way to the undesirable result, can they be altered to effect a better result? We have insufficient data at the present time to arrive at any conclusions regarding the answer to this question. Further studies are contemplated.
